Key facts
- TG Therapeutics stock rose following the release of early-stage trial data.
- The data pertains to the company's Briumvi injectable treatment.
TG Therapeutics' stock experienced a rise following the release of early-stage trial data for its Briumvi injectable. The company's announcement indicates positive developments in the testing of this new treatment. The specific details of the trial data were not provided in the initial announcement, but the market reaction suggests investor optimism regarding the potential of Briumvi.